By Benjamin Horney ( January 19, 2022, 12:19 PM EST) -- Belgium-based biotechnology company UCB has agreed to buy California rare disease focused drugmaker Zogenix for up to $1.9 billion, the companies said Wednesday, in a deal stitched together by respective legal advisers Covington & Burling LLP and Latham & Watkins LLP....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.